RxDoctor Payments DataLook up a doctor →

Robert Given, MD

Urology · Virginia Beach, VANPI 1669450680

Payments from drug & device makers

$8,741,983in general payments, 2019–2025

Across 1,244 payments — averaging $7027.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medivation LLC.$2.5M
  • Pfizer$2M
  • Merck$1.9M
  • Janssen Research & Development, LLC$907K
  • Astellas Pharma Global Development$406K
  • Sumitomo Pharma America, Inc.$396K
  • plus $639K from 43 others
$20,741in research payments, 2019–2025

Across 2 payments — averaging $10,370 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dendreon Pharmaceuticals LLC$21K

What the payments were for

  • Consulting fees$28,17618%
  • Speaking & faculty fees$101,94965%
  • Grants$1250%
  • Travel & lodging$16,88811%
  • Food & beverage$9,8526%
  • Education$2920%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,741,983 in reported general payments places this provider in the 95th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$1,316,438
Medicare patients
1,681
Services billed
36,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide202$3,017,248
NubeqaDarolutamide88$1,203,449
XtandiEnzalutamide88$1,162,817
OrgovyxRelugolix81$234,385
Abiraterone Acetate104$157,808
MyrbetriqMirabegron16$13,514
Tamsulosin Hcl406$5,362
Trospium Chloride46$2,445
Finasteride83$1,128
Dutasteride20$592
Alfuzosin Hcl ErAlfuzosin Hcl30$557
Oxybutynin Chloride ErOxybutynin Chloride25$502
NitrofurantoinNitrofurantoin Macrocrystal14$453
Bicalutamide13$413
Prednisone83$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$80,872$3,017,248202 claims
BayerNubeqa$135,231$1,203,44988 claims
Astellas Pharma US IncXtandi, Myrbetriq$409$1,176,331104 claims
Sumitomo Pharma America, Inc.Orgovyx$396,292$234,38581 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$3,015$157,808104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 urology providers in Virginia.

Other urology in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →